Aggregator
The past, present and future of de novo protein design
GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
Increase in wild animal consumption across Central Africa
Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup
Training language models to be warm can reduce accuracy and increase sycophancy
Cytoplasmic competition between separate parental pronuclei in zygotes
Engineering tough blood clots for rapid haemostasis and enhanced regeneration
Translation-dependent degradation of <i>cas12</i> mRNA triggered by an anti-CRISPR
Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex
Transdimensional anomalous Hall effect in rhombohedral thin graphite
Improving access to essential medicines via decision-aware machine learning
Digital quantum magnetism on a trapped-ion quantum computer
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1
Recycling of spin-triplet excitons in organic photovoltaics
Decarboxylative alkylation of alkenes
Immunity gets a boost from a surprising place — breakfast
Reply to: Overestimating outsourced biodiversity loss may misguide policy
Overestimating outsourced biodiversity loss may misguide policy
Author Correction: Broadly stable atmospheric CO<sub>2</sub> and CH<sub>4</sub> levels over the past 3 million years
A forgotten drug is giving new hope to kids with a rare disease
A decades-old drug once used to treat sleeping sickness is now showing surprising promise against an ultra-rare and life-threatening genetic disorder called Bachmann-Bupp syndrome (BABS). Early patient treatments suggest the drug, DFMO, may ease severe symptoms by targeting the underlying genetic malfunction. Researchers have already treated a handful of patients with encouraging results, but progress has been slowed by regulatory and logistical hurdles.